EMILY NEWMAN: Open Payments
NPI 1629784251 · NEWPORT, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,456 in 76 payments from 14 companies in 2025. Trend: 2023 $560 · 2024 $857 · 2025 $1,456
Food & beverage: $1,456
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $321 |
| Janssen Pharmaceuticals, Inc | 12 | $218 |
| Vanda Pharmaceuticals Inc. | 9 | $194 |
| E.R. Squibb & Sons, L.L.C. | 9 | $176 |
| Otsuka America Pharmaceutical, Inc. | 10 | $163 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $75 |
| Teva Pharmaceuticals USA, Inc. | 5 | $73 |
| Axsome Therapeutics, Inc. | 3 | $65 |
| Neurocrine BioSciences, Inc. | 2 | $44 |
| Alkermes, Inc. | 1 | $35 |
Products named: VRAYLAR, INVEGA SUSTENNA, COBENFY, FANAPT, ABILIFY ASIMTUFII, REXULTI, HETLIOZ, CAPLYTA.
Industry payments across AR — which companies pay providers there.
